Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


BT Pharma successfully closes EUR 2.8 million (USD 4M) financing round

Toulouse, France - Wednesday - September 17 2008 - BT Pharma, a biopharmaceutical firm developing novel immunotherapeutics for HPV-associated diseases and cancers, announces today that it has successfully closed a new financing round of EUR 2,825,000 (USD 4M). The round was led by Edmond de Rothschild Investment Partners (EdRIP). Longstanding shareholders Fonds d'Amorçage Midi-Pyrenees (FAM) managed by the team of Icso Private Equity, BrevImmo, LBP, Beaufagne, Whitehall and the Management of the company also participated. The funds will enable the Company to take its lead immunotherapeutic candidate, ProCervix(R), through the final stages of its preclinical development and to prepare to enter into clinical trials.

ProCervix(R) primarily aims to treat women who are already infected by Human Papillomavirus and who therefore run the risk of developing high-grade neoplasia and/or cervical cancer. ProCervix(R) exploits the unique characteristics of the Adenylate Cyclase vector (CyaA) which, upon injection, has the unique characteristic of selectively delivering its antigen load into the appropriate immune cell. This results in the activation of a strong and specific cellular immune response in the patient.

'The awareness of the medical need to treat HPV-related infections, neoplasia and cancer is increasing,' said Dr. Benedikt Timmerman, Chief Executive of BT Pharma.'Our clinical timelines allow BT Pharma to be one of few key players in this exciting new market. This investment is instrumental to complete the preclinical development of our lead candidate ProCervix(R) and to bring this promising immuno-therapeutic into the clinic.'

'We have followed BT Pharma's progress and have built over time a constructive relationship with the management,' said Raphael Wisniewski, partner at EdRIP. 'We have now decided to invest in this company as BT Pharma's lead program appears to be one of the most exciting approaches in this area and is on track for its 'First-in-Man' clinical trial.'

'We have invested in BT Pharma through FAM, our seed investment fund, from its incorporation in the Midi-Pyrenees Region,' said Jean-Michel Petit, Investment Director at Icso Private Equity team and IRDI. 'As one of the early investors in the company, we are very pleased with its development. BT Pharma's innovative Adenylate Cyclase vector is extremely well adapted for 'therapeutic' vaccination, and can give rise to a new class of drugs with broad applications in infectious diseases and cancer.'

About BT Pharma S.A.
BT Pharma is a privately held biopharmaceutical company incorporated in October 2001 and spun out of the Institut Pasteur in October 2002. The company headquarters and laboratories are currently based in Labege (Toulouse) France. The company strives to improve the well-being of people through the development of therapeutic vaccines for infection, dysplasia and cancer provoked by the Human Papillomavirus (HPV).
For more information:

About Edmond de Rothschild Investment Partners (EdRIP)
Paris-based Edmond de Rothschild Investment Partners is dedicated to minority investments into privately-owned companies. It has currently EUR 650M under management which is being invested primarily as life sciences venture capital and growth capital.

Its Life Science Team of six professionals brings together over 30 years of experience in the Life Science industry and more than 50 years of private equity and venture capital experience. The team has approximately EUR 300M under management after having recently raised EUR 150M through BioDiscovery III. Edmond de Rothschild Investment Partners is an independently managed affiliate of La Compagnie Financiere Edmond de Rothschild Banque.
For more information please visit:

About Icso Private Equity
ICSO Private Equity manages Private Equity funds (FCPR and FIP) dealing with Venture capital, LBO and Growth capital. The 18-people team is member of the economic interest group IRDI and has been performing for 26 years. Based in Toulouse and Bordeaux, ICSO Private Equity is the largest French independent regional actor. The company manages approximately EUR 200M in assets, and invests from EUR 0.5M to 10M in projects primarily in the West and South of France, and in the north of Spain.
For more information contact:

Mr Raphael Wisniewski
Edmond de Rothschild Investment Partners
47 rue du Faubourg Saint Honoré
75401 Paris Cedex 08, France
Tel: +33 (0) 1 40 17 31 44

Mr Jean-Michel Petit
Sylvie Ives - Press contact
ICSO Private Equity
18, place Dupuy B.P. 808
31000 Toulouse, France
Tel : +33 (0)5 34 41 74 08)
Tel: +33 (0)6 84 14 11 15

For more information please contact:
Andrew Lloyd & Associates
Andrew Lloyd/ Neil Hunter
Tel: +44 1273 675100 /

Publisher Contact Information:

Edmond de Rothschild Investment Partners
+33 (0) 1 40 17 31 44

Company profile of Genticel (formerly known as BT Pharma)
Past press releases of Genticel (formerly known as BT Pharma).


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 15€2.4MMaterials
Nov 15€6.0MArtificial Intelligence
Nov 15€3.5MSoftware development
Nov 15N/AInternet services
Nov 14€4.5MOther Software
Nov 14€4.7MBusiness applications
Nov 14€9.0MKnowledge management

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.